Beckman Coulter, Inc. Announces Conference Call To Discuss Fourth Quarter and Year-Ended 2002 Results on Monday, January 27, 2003.Business Editors FULLERTON, Calif.--(BUSINESS WIRE)--Jan. 14, 2003 Beckman Coulter, Inc. (NYSE NYSE See: New York Stock Exchange : BEC) announced today it will host a conference call to discuss the company's fourth quarter and 2002 year-end results on Monday, January 27, 2003 at 9:00 a.m. EST EST electroshock therapy. EST abbr. electroshock therapy . Earnings will be released earlier that morning. The call will be hosted by John P. Wareham, chairman, president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , and Amin Khalifa, vice president finance and CFO See Chief Financial Officer. . The call may be accessed by dialing (877) 516-3365 or (706) 679-3246 and asking for the Beckman Coulter conference call or reservation 7553028. There will also be a live webcast of the call. It will be accessible to all investors through Beckman Coulter's website at www.beckmancoulter.com or at www.streetevents.com . When accessing the webcast through the Beckman Coulter site, select "more IR info" under Investor Relations Investor relations The process by which the corporation communicates with its investors. and find the call listed under "What's New". The webcast will be archived on both websites for future on-demand replay through Monday, February 10, 2003. Beckman Coulter, Inc. is a global biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. company, headquartered in Fullerton, California. The company develops and markets instruments, chemistries, software and supplies that simplify and automate laboratory processes throughout the biomedical testing continuum. Through pioneering medical research and drug discovery, specialty testing, and patient care diagnostics, Beckman Coulter supports all phases of the battle against disease. Annual sales for the company totaled $2 billion in 2001, with 62% of this amount generated by recurring revenue from supplies, test kits and services. For more information, visit www.beckmancoulter.com. |
|
||||||||||||||||

Printer friendly
Cite/link
Email
Feedback
Reader Opinion